Tetrabenazine is neuroprotective in Huntington's disease mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Httexp causes selective degeneration of striatal medium spiny neurons (MSN) in HD patients. A number of previous studies suggested that dopamine signaling plays an important role in HD pathogenesis. A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine (TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA. TBZ acts by reducing dopaminergic input to the striatum. Results: In previous studies we demonstrated that long-term feeding with TBZ (combined with L-Dopa) alleviated the motor deficits and reduced the striatal neuronal loss in the yeast artificial chromosome transgenic mouse model of HD (YAC128 mice). To further investigate a potential beneficial effects of TBZ for HD treatment, we here repeated TBZ evaluation in YAC128 mice starting TBZ treatment at 2 months of age ("early" TBZ group) and at 6 months of age ("late" TBZ group). In agreement with our previous studies, we found that both "early" and "late" TBZ treatments alleviated motor deficits and reduced striatal cell loss in YAC128 mice. In addition, we have been able to recapitulate and quantify depression-like symptoms in TBZ-treated mice, reminiscent of common side effects observed in HD patients taking TBZ. Conclusions: Our results further support therapeutic value of TBZ for treatment of HD but also highlight the need to develop more specific dopamine antagonists which are less prone to side-effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451 · cited 1×
“Immobility in the forced swim test (FST) is a commonly used for measurement of depression in rodents [63-65].”
BackgroundBehavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 1×
“Immobility in the forced swim test (FST) is a commonly used for measurement of depression in rodents [63-65].”
BackgroundCha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Tadori, Y., Kitagawa, H., Forbes, R. A., McQuade, R. D., Stark, A., & Kikuchi, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.031 · Cited by 69 · cited 1×
“A novel compound huntexil (pridopidine; ACR16) is a modulator of D2 receptor activity [61,62] which has been recently developed by NeuroSearch for treatment of movement and psychiatric disorders.”
Background
Cited by
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Salamone, J. D., Yohn, S. E., López-Cruz, L., San Miguel, N., & Correa, M. (2016) · Brain · doi:10.1093/brain/aww050 · Cited by 350
BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
Xie, Y., Hayden, M. R., & Xu, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1637-10.2010 · Cited by 236
“The later onset may also explain why we did not detect gait abnormalities that were reported in FVB/N YAC128 mice (Wang et al., 2010).”
BackgroundMesolimbic Dopamine and the Regulation of Motivated Behavior
Salamone, J. D., Pardo, M., Yohn, S. E., López-Cruz, L., SanMiguel, N., & Correa, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_383 · Cited by 204
Dopamine, effort-based choice, and behavioral economics: basic and translational research.
Salamone, J. D., Correa, M., Yang, J.-H., Rotolo, R., & Presby, R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00052 · Cited by 142
Metadata
- Authors
- Wang, H., Chen, X., Li, Y., Tang, T.-S., & Bezprozvanny, I.
- Venue
- Molecular Neurodegeneration
- Published
- 2010-04-26
- Volume
- 5
- Issue
- 1
- Pages
- 18-18
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W2125105780
- Cited by
- 90
- References
- 6
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tetrabenazine is neuroprotective in Huntington's disease mice. https://app.cochat.ai/papers/10.1186/1750-1326-5-18
- The paper
- Wang, H., Chen, X., Li, Y., Tang, T.-S., & Bezprozvanny, I. (2010). Tetrabenazine is neuroprotective in Huntington's disease mice. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-5-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.